CNCE News and Press, Concert Pharmaceuticals Inc. From 06/16/22

Gainers: Cortexyme (CRTX) +7.9%. GoodRx Holdings (GDRX) +5.4%. Concert Pharmaceuticals (CNCE) +4.9%. Roku (ROKU) +4.3%. Mercer International (MERC) +4.3%. Losers: Rhythm Pharmaceuticals (RYTM) -8.5%. Redbox Entertainment (RDBX) -3.6%. KemPharm (KMPH) -3.1%. SS&C Technologies Hol...

Concert Pharmaceuticals has a JAK inhibitor for alopecia areata (AA) that may be superior to competitive products. The company cites a figure of 1.5m US patients with AA. Published literature cites a prevalence of 700,000 patients and only 300,000 with moderate to severe AA. The f...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY. A webcast of the JMP fireside chat may be accessed in the Investors secti...

Penny stocks can be your greatest asset or worst enemy, depending on how you trade them. Their low prices lend themselves to considerable gain potential, and I’m not just talking 5 or 10%. Almost daily, we see stocks under $5 explode by 50% or more…yes, 50% or more. But with t...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the publication of safety and efficacy data from the randomized, double-blind, placebo-controlled dose-ranging Phase 2 clinical trial for CTP‑543 in the Journal of the American Academy of Dermatology (JAAD) . CT...

Concert Pharmaceuticals (NASDAQ:CNCE) has raised $66.4M in gross proceeds through its previously announced underwritten public offering of 10M shares and exercise of warrants. Each share was offered at $4.75. Aggregate gross proceeds to Concert from this offering were $47.5M. The pharma firm ...

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share. The aggregate gross proceeds to Concert from this offering were $47.5 million, bef...

Alopecia Areata (AA) is an autoimmune disease in which the body mistakenly attacks one's hair follicles resulting in hair loss. AA affects men, women, and children of different ages & ethnicities. There is currently no approved treatment for AA, but a close 3-way race between LLY,...

Gainers: Immix Biopharma (IMMX) +37%. Bright Green (BGXX) +29%. Repare Therapeutics (RPTX) +29%. Yumanity Therapeutics (YMTX) +24%. PDS Biotechnology (PDSB) +15%. Losers: Zosano Pharma (ZSAN) -48%. Immunic (IMUX) -41%. Aeglea BioTherapeutics (AGLE) -40%...

Concert Pharmaceuticals (NASDAQ:CNCE) priced its underwritten public offering of 10M shares at a public offering price of $4.75/share Gross proceeds are expected to be ~$47.5M. Underwriters granted 30-day option to purchase up to an additional 1.5M shares. Offering is expected to cl...